Abiraterona en cáncer de próstata hormono-sensible metastásico

13 / 32

Clinical guidelines have been updated to include AA+P+ADT as
recommended first-line treatment for patients with NDx mHSPC
Guideline Recommendations
EAU 20181
Updated in
Mar’ 2018
• Offer castration, with or without an antiandrogen, to patients unfit for, or unwilling to consider, castration combined with
docetaxel or abiraterone acetate + prednisone
ESMO 20172,3
Updated in
Sep’ 2017
• ADT plus abiraterone/prednisone may be considered as first-line treatment for metastatic,
hormone-naïve disease
SEOM 20174
Updated in
Nov’ 2017
• Abiraterone plus ADT is recommended in mHSPC patients
1EAU Guidelines . 2018; 2Parker C et al. Ann Oncol 2015;26 Suppl 5:v69-77; 3ESMO eUpdate Sept 2017; 4Cassinello J et
al. Clin Trans Oncol 2018;20(1):57-68; 5 Morris MJ et al. J Clin 18; doi:JCO.2018.2078.0619; 6NCCN v1 2018
Guideline Recommendations
ASCO 20185
Updated in
Apr’ 2018
Abiraterone plus ADT
• For men with high-risk de novo metastatic non-castrate prostate cancer, the addition of abiraterone
to ADT should be offered per LATITUDE
• For men with lower-risk de novo metastatic non-castrate prostate cancer, abiraterone may be
offered per STAMPEDE
• The appropriate regimen is abiraterone 1,000mg with either prednisolone or prednisone 5mg once
daily until treatment(s) for mCRPC are initiated
NCCN 20186
Updated in
Feb’ 2018
• ADT† and abiraterone with prednisone
Clinical guidelines have been updated to include AA+P+ADT as
recommended first-line treatment for patients with NDx mHSPC
Guideline Recommendations
EAU 20181
Updated in
Mar’ 2018
• Offer castration, with or without an antiandrogen, to patients unfit for, or unwilling to consider, castration combined with
docetaxel or abiraterone acetate + prednisone
ESMO 20172,3
Updated in
Sep’ 2017
• ADT plus abiraterone/prednisone may be considered as first-line treatment for metastatic,
hormone-naïve disease
SEOM 20174
Up ated in
Nov’ 2017
• Abiraterone plus ADT is recommended in mHSPC patients
1EAU Guidelines . 2018; 2Parker C et al. Ann Oncol 2015;26 Supp 3ESMO eUpdate Sept 2017; 4Cassinello J et
al. Clin Trans Oncol 2018;20(1):57-68; 5Morris MJ et al. J Clin Oncol 2018; doi:JCO.2018.2078.0619; 6NCCN v1 2018
5
Abiraterone plus ADT
• For men with high-risk de novo metastatic non-castrate prostate cancer, the addition of abiraterone
to ADT should be offered per LATITUDE
• For men with lower-risk de novo metastatic non-castrate prostate cancer, abiraterone may be
offered per STAMPEDE
• The appropriate regimen is abiraterone 1,000mg with either prednisolone or prednisone 5mg once
daily until treatment(s) for mCRPC are initiated
6
• ADT † and abiraterone with prednisone